调节性T细胞与缺血性脑卒中危险因素的相关性

doi:10.3969/j.issn.1004-583X.2022.04.016

摘要/Abstract

摘要：

在全球范围内,脑卒中具有极高的发病率、死亡率和致残率,给家庭和社会带来了沉重的负担,但目前其治疗方法仍十分有限。控制危险因素是预防缺血性脑卒中发生的关键。越来越多的证据表明,免疫炎症反应在脑卒中的病理生理过程中起到重要作用。动脉粥样硬化、高血压、高胆固醇血症、心脏疾病等是缺血性脑卒中的危险因素,调节性T细胞与之密切相关。调节性T细胞是CD4⁺T细胞的一个亚群,在维持免疫动态平衡、预防自身免疫和炎症等方面发挥重要作用。本文将对调节性T细胞与缺血性脑卒中危险因素进行综述,以期为缺血性脑卒中的预防及治疗提供新思路。

关键词: 调节性T细胞, 缺血性脑卒中, 免疫, 炎症

中图分类号:

R743.3

何洪真, 吕佩源. 调节性T细胞与缺血性脑卒中危险因素的相关性[J]. 临床荟萃, 2022, 37(4): 369-372.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.04.016

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I4/369

参考文献 36

[1]	Dong Y, Guo ZN, Li Q. et al. Chinese stroke association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of spontaneous subarachnoid haemorrhage[J]. Stroke Vasc Neurol, 2019, 4(4): 176-181. doi: 10.1136/svn-2019-000296 pmid: 32030200
[2]	Chen HS, Chen X, Li WT. et al. Targeting RNS/caveolin-1/MMP signaling cascades to protect against cerebral ischemia-reperfusion injuries: Potential application for drug discovery[J]. Acta Pharmacol Sin, 2018, 39(5): 669-682. doi: 10.1038/aps.2018.27 URL
[3]	Santamaría-Cadavid M, Rodríguez-Castro E, Rodríguez-Yáñez M. et al. Regulatory T cells participate in the recovery of ischemic stroke patients[J]. BMC Neurol, 2020, 20(1): 68. doi: 10.1186/s12883-020-01648-w pmid: 32111174
[4]	Sakaguchi S, Sakaguchi N, Asano M. et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol, 1995, 155(3): 1151-1164. pmid: 7636184
[5]	Ono M. Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes[J]. Immunology, 2020, 160(1): 24-37. doi: 10.1111/imm.13178 URL
[6]	Tao JH, Cheng M, Tang JP. et al. Foxp3, regulatory T cell, and autoimmune diseases[J]. Inflammation, 2017, 40(1): 328-339. doi: 10.1007/s10753-016-0470-8 URL
[7]	Battaglia M, Stabilini A, Migliavacca B. et al. Rapamycin promotes expansion of functional CD4⁺CD25⁺FOXP3⁺ regulatory T cells of both healthy subjects and type 1 diabetic patients[J]. J Immunol, 2006, 177(12): 8338-8347. doi: 10.4049/jimmunol.177.12.8338 pmid: 17142730
[8]	Trzonkowski P, Szarynska M, Mysliwska J. et al. Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy[J]. Cytometry A, 2009, 75(3): 175-188.
[9]	Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: Mechanisms of differentiation and function[J]. Annu Rev Immunol, 2012, 30: 531-564. doi: 10.1146/annurev.immunol.25.022106.141623 pmid: 22224781
[10]	Wang Y, Zhang JH, Sheng J. et al. Immunoreactive cells after cerebral ischemia[J]. Front Immunol, 2019, 10: 2781. doi: 10.3389/fimmu.2019.02781 URL
[11]	Drieu A, Buendia I, Levard D. et al. Immune responses and anti-inflammatory strategies in a clinically relevant model of thromboembolic ischemic stroke with reperfusion[J]. Transl Stroke Res, 2020, 11(3): 481-495. doi: 10.1007/s12975-019-00733-8 URL
[12]	Ito M, Komai K, Nakamura T. et al. Tissue regulatory T cells and neural repair[J]. Int Immunol, 2019, 31(6): 361-369. doi: 10.1093/intimm/dxz031 URL
[13]	Mao L, Li P, Zhu W. et al. Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke[J]. Brain, 2017, 140(7): 1914-1931. doi: 10.1093/brain/awx111 URL
[14]	Ito M, Komai K, Mise-Omata S. et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery[J]. Nature, 2019, 565(7738): 246-250. doi: 10.1038/s41586-018-0824-5 URL
[15]	Li P, Gan Y, Sun BL. et al. Adoptive regulatory T-cell therapy protects against cerebral ischemia[J]. Ann Neurol, 2013, 74(3): 458-471. doi: 10.1002/ana.23815 URL
[16]	Sakai R, Komai K, Iizuka-Koga M. et al. Regulatory T cells: Pathophysiological roles and clinical applications[J]. Keio J Med, 2020, 69(1): 1-15. doi: 10.2302/kjm.2019-0003-OA URL
[17]	Klein M, Bopp T. Cyclic AMP represents a crucial component of treg cell-mediated immune regulation[J]. Front Immunol, 2016, 7: 315.
[18]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国脑血管病一级预防指南2019[J]. 中华神经科杂志, 2019, 52(9): 684-708.
[19]	He X, Liang B, Gu N. Th17/Treg imbalance and atherosclerosis[J]. Dis Markers, 2020: 8821029.
[20]	Gewaltig J, Kummer M, Koella C. et al. Requirements for CD8 T-cell migration into the human arterial wall[J]. Hum Pathol, 2008, 39(12): 1756-1762. doi: 10.1016/j.humpath.2008.04.018 pmid: 18706675
[21]	Ait-Oufella H, Salomon BL, Potteaux S. et al. Natural regulatory T cells control the development of atherosclerosis in mice[J]. Nat Med, 2006, 12(2): 178-180. pmid: 16462800
[22]	Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells[J]. Arterioscler Thromb Vasc Biol, 2015, 35(2): 280-287. doi: 10.1161/ATVBAHA.114.303568 URL
[23]	Matrougui K, Abd Elmageed Z, Kassan M. et al. Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice[J]. Am J Pathol, 2011, 178(1): 434-441. doi: 10.1016/j.ajpath.2010.11.034 pmid: 21224080
[24]	Radwan E, Mali V, Haddox S. et al. Treg cells depletion is a mechanism that drives microvascular dysfunction in mice with established hypertension[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(2): 403-412. doi: 10.1016/j.bbadis.2018.10.031 URL
[25]	Iulita MF, Duchemin S, Vallerand D. et al. CD4(+) regulatory T lymphocytes prevent impaired cerebral blood flow in angiotensin Ⅱ-induced hypertension[J]. J Am Heart Assoc, 2019, 8(1): e009372. doi: 10.1161/JAHA.118.009372 URL
[26]	Gu X, Li Y, Chen S. et al. Association of lipids with ischemic and hemorrhagic stroke: A prospective cohort study among 267500 Chinese[J]. Stroke, 2019, 50(12): 3376-3384. doi: 10.1161/STROKEAHA.119.026402 URL
[27]	Amarenco P, Bogousslavsky J, Callahan A. et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med, 2006, 355(6): 549-559. doi: 10.1056/NEJMoa061894 URL
[28]	Katsanos AH, Hart RG. New horizons in pharmacologic therapy for secondary stroke prevention[J]. JAMA Neurol, 2020, 77(10): 1308-1317. doi: 10.1001/jamaneurol.2020.2494 URL
[29]	Amarenco P, Kim JS, Labreuche J. et al. A comparison of two LDL cholesterol targets after ischemic stroke[J]. N Engl J Med, 2020, 382(1): 9. doi: 10.1056/NEJMoa1910355 URL
[30]	Maganto-Garcia E, Tarrio ML, Grabie N. et al. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia[J]. Circulation, 2011, 124(2): 185-195. doi: 10.1161/CIRCULATIONAHA.110.006411 pmid: 21690490
[31]	Mailer RKW, Gistera A, Polyzos KA. et al. Hypercholesterolemia enhances T cell receptor signaling and increases the regulatory T cell population[J]. Sci Rep, 2017, 7(1): 15655. doi: 10.1038/s41598-017-15546-8 URL
[32]	Rao LN, Ponnusamy T, Philip S. et al. Hypercholesterolemia induced immune response and inflammation on progression of atherosclerosis in Apob(tm2Sgy) Ldlr(tm1Her)/J mice[J]. Lipids, 2015, 50(8): 785-797. doi: 10.1007/s11745-015-4046-4 URL
[33]	Hu H, Wu J, Cao C. et al. Exosomes derived from regulatory T cells ameliorate acute myocardial infarction by promoting macrophage M2 polarization[J]. IUBMB Life, 2020, 72(11): 2409-2419. doi: 10.1002/iub.2364 URL
[34]	Mukhopadhyay S, Varma S, Mohan Kumar HN. et al. Circulating level of regulatory T cells in rheumatic heart disease: An observational study[J]. Indian Heart J, 2016, 68(3): 342-348. doi: 10.1016/j.ihj.2015.08.009 pmid: 27316488
[35]	Sulzgruber P, Koller L, Winter MP. et al. The impact of CD4(+)CD28(null) T-lymphocytes on atrial fibrillation and mortality in patients with chronic heart failure[J]. Thromb Haemost, 2017, 117(2): 349-356. doi: 10.1160/TH16-07-0531 URL
[36]	Hammer A, Sulzgruber P, Koller L. et al. The prognostic impact of circulating regulatory T lymphocytes on mortality in patients with ischemic heart failure with reduced ejection fraction[J]. Mediators Inflamm, 2020: 6079713.

调节性T细胞与缺血性脑卒中危险因素的相关性

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张晓璐, 李红山. 自身免疫性肝炎发病机制研究进展——聚焦“肠道菌群与免疫系统相互作用”[J]. 临床荟萃, 2024, 39(2): 177-182.
[2]	宋佳亮, 蒋英杰, 孔瑞娜, 蔡青, 高洁. 以IgE和嗜酸粒细胞升高伴多发淋巴结肿大为主要表现的IgG4相关性疾病1例报告[J]. 临床荟萃, 2024, 39(1): 57-60.
[3]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[4]	李阳, 默峰, 辛志飞, 王倩, 邓新娜. 特殊临床表现多系统免疫相关不良事件1例[J]. 临床荟萃, 2023, 38(7): 633-637.
[5]	裴红运, 文洁, 山凤莲. 结核病患者淋巴细胞程序性细胞死亡受体-1表达变化的研究进展[J]. 临床荟萃, 2023, 38(7): 659-662.
[6]	孙星星, 林海. 儿童重症肺炎的免疫功能变化及预后危险因素[J]. 临床荟萃, 2023, 38(6): 521-525.
[7]	程婷婷, 齐彩英, 张雪莲, 肖梦, 隋伟行, 李小燕, 刘建英. 重症肺炎支原体肺炎与血清IgE和C反应蛋白水平的相关性及临床特征[J]. 临床荟萃, 2023, 38(5): 433-437.
[8]	冷婉铜, 陶洁. 多发性骨髓瘤患者治疗后发生静脉血栓栓塞的危险因素[J]. 临床荟萃, 2023, 38(4): 340-345.
[9]	周大伟, 费长东, 刘宇鹏, 张华霖. 获得性免疫缺陷综合征合并重症肺炎1例并文献复习[J]. 临床荟萃, 2023, 38(4): 352-355.
[10]	易静静, 圈启芳, 马婕. 调节小胶质细胞反应性:糖尿病视网膜病变新见解[J]. 临床荟萃, 2023, 38(4): 364-368.
[11]	谢少为, 吕小涵, 董艳红, 吕佩源. 抗炎细胞因子在阿尔茨海默病中的研究进展[J]. 临床荟萃, 2023, 38(2): 185-188.
[12]	代菁, 陈华茜. 血液透析患者自发性肾破裂1例并文献复习[J]. 临床荟萃, 2023, 38(12): 1107-1111.
[13]	王思源, 王利, 温新然, 李小青. 新型冠状病毒感染后儿童多系统炎症综合征2例并文献复习[J]. 临床荟萃, 2023, 38(12): 1112-1116.
[14]	黄小敏, 赵旭辉, 达德转, 马桃梅, 李红玲. EB病毒感染和程序性死亡受体配体1表达在晚期胃癌免疫靶向治疗中的研究进展[J]. 临床荟萃, 2023, 38(11): 1048-1052.
[15]	何培华, 周幸福, 洪炜鸿, 王利纯, 刘素君, 金玉燕, 曾佳豪, 刘立昌. IgG4相关性肾病4例临床分析[J]. 临床荟萃, 2023, 38(11): 1016-1021.